Anchiano Therapeutics jumps after Chemomab merger

Adi Mor  / Photo: Eyal Izhar, Globes
Adi Mor / Photo: Eyal Izhar, Globes

The merger will create a company focused on advancing Chemomab’s lead product, CM-101, for the treatment of fibrosis-related diseases.

Israeli drug developer Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (formerly Biocancell) has reached the end of the road 16 years after it was founded. It is merging with clinical-stage biotech company Chemomab Ltd. have announced a merger. The merger will create a public company focused on advancing Chemomab’s lead product, CM-101, for the treatment of fibrosis-related diseases.

Anchiano had been developing a cancer treatment that did not meet its end targets in clinical trials. Since the announcement of the merger, Anchiano's share price has risen 168% to give a market cap of $32 million but is still 50% below its market cap in 2019.

Chemomab will also seek to complete a private placement financing to advance CM-101 into Phase II clinical trials in rare fibrotic indications, as well to further develop Chemomab’s earlier-stage pipeline. Initial efforts will focus on orphan indications including primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), which are inflammatory-fibrotic diseases affecting multiple organs such as the liver (in PSC) and skin and lungs (in SSc). Both indications have a significant unmet need, with patients suffering from debilitating symptoms and no FDA-approved disease modifying treatment options. The merged company also expects to advance CM-101 into a Phase IIa trial to evaluate the antibody’s anti-fibrotic effect in patients diagnosed with non-alcoholic steatohepatitis (NASH).

Anchiano chairman Stan Polovets said, "Following a comprehensive review of strategic alternatives, Anchiano’s Board of Directors has concluded that the proposed transaction with Chemomab is in the best interest of our shareholders. Chemomab’s CM-101 has demonstrated positive clinical results, with a novel mechanism of action that has potential to become an important option for patients with debilitating fibrotic diseases. We intend to hold a special meeting of Anchiano’s shareholders in the first quarter of 2021 to vote on this merger."

Chemomab cofounder and CEO Dr. Adi Mor said, "Our lead compound, CM-101, has shown very positive safety and anti-fibrotic biomarker activity in a Phase Ib study, and with the antibody advancing into Phase II trials in two orphan fibrotic indications, we believe it is the right time in our lifecycle to move into the public equity markets. We are excited about the next chapter of growth for Chemomab, and the ability to bring the important effects of CM-101 through clinical development and to patients."

Upon closing of the transaction, the combined company will assume the name Chemomab Therapeutics, Ltd and will be led by Chemomab’s management team, headed by Dr. Mor.

Published by Globes, Israel business news - en.globes.co.il - on December 15, 2020

© Copyright of Globes Publisher Itonut (1983) Ltd. 2020

Adi Mor  / Photo: Eyal Izhar, Globes
Adi Mor / Photo: Eyal Izhar, Globes
Amnon Shashua  credit: Eyal Izhar Shashua's Mentee Robotics unveils robot for manual work

MenteeBot V3.0 takes on lifting tasks that would typically be strenuous for human workers over extended periods.

New housing credit: Satenik Guzhanina Shutterstock 50% of housing deals in 2024 were developer loans

What made 2024 distinct was that 50% of deals involved special offers by contractors and developers for apartments not yet built, the Ministry of Finance reports.

Donald Trump  credit: Reuters/Brendan McDermid Trump administration reaffirms AI chip restrictions on Israel

Sources say the US will demand Israel passes regulations to prevent tech leakage to China and may even include removal of the restrictions as part of a multilateral Middle East agreement.

Accountant General Yali Rothenberg credit: Cadya Levy Israel raises $5b international bond

Accountant General: This is an important public offering that indicates the financial stability of the State of Israel and the high confidence of global investors in the Israeli economy.

Check Point Chairman Gil Shwed and CEO Nadav Zafrir credit: Check Point Check Point teams with Wiz to challenge Palo Alto

The veteran cybersecurity company has formed a strategic partnership with Israeli company Wiz to provide end-to-end cloud security.

Mobileye autonomous taxi  credit: Mobileye Mobileye to team with Lyft on Robotaxis in Dallas

Ridesharing giant Lyft CEO David Risher said that his company will launch the robotaxis in Dallas in 2026.

Voyantis founders credit: Guy Sidi Israeli predictive AI co Voyantis raises $41m

Voyantis combines predictive and prescriptive AI to eliminate guesswork traditionally involved in assessing a customer’s potential value.

Karin Eibschitz Segal. credit: Ohad Falik Intel Israel CEO named interim head of DCAI

Intel Israel CEO Karin Eibschitz Segal has been appointed Intel's interim head of Intel's data center and artificial intelligence, the third most important position at the US chipmaker.

Shekel v dollar  credit: Tali Bogdanovsky using Adobe Firefly Shekel weaker amid hostage release uncertainties

Bank Hapoalim: This is a correction, the shekel will continue to strengthen.

Avi Simhon, Bezalel Smotrich and Yogev Gradus credit: Yossi Cohen, Noam Moskovich/Knesset Spokesperson, Amit Shabi/Yediot Ahronot Israeli gov't mulls tax cuts as deficit narrows

National Economic Council chairman Prof. Avi Simhon: If we are convinced this is a continuing trend, the first tax I would reduce is cutting VAT back to 17%.

Elbit Systems president and CEO Bezhalel Makhlis credit: Assaf Shilo Israel Sun Prioritizing Israel creates problems for Elbit

Ministry of Defense demands to supply Israel first has meant overseas deliveries have been delayed, irking the Philippines in particular.

monday.com co-CEOs eran Zinman and Roy Mann credit: Netanel Tobias monday.com soars on strong Q4 results

After beating the analysts on revenue and profit, the work operating systems company is now the fourth most valuable Israeli company on Wall Street.

Mark Zuckerberg credit: Reuters Manuel Orbegozo Meta lays off 40 in Israel

Meta (Facebook) is simultaneously laying off 5% of its employees at all the company's centers worldwide including in Israel.

Elbit Systems credit: Shutterstock Elbit awarded $100m European digital firing deal

The Israeli defense electronics company will provide a Joint National Digital Fire Command Center (JNDFC) to a European country and integrate it with the customer’s strategic and tactical firing platforms.

Finance Minister Bezalel Smotrich credit Danny Shem Tov, Knesset Spokesperson Israel's fiscal deficit narrows after record state revenues

The improvement in the fiscal deficit follows all-time record state revenues of NIS 63.1 billion in January, and a fall in government spending.

Sender Cohen, Michael Eisenberg and Adam Fisher credit: Aleph, Eyal Izhar and Bessemer Investors raising $800m for Israeli research institute Nevo Labs

US investor Sender Cohen says Nevo Labs will focus on research for long term commercial development in three key research areas: AI, quantum computing, and synthetic biology.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018